Cargando…

Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?

The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database to study the associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thotamgari, Sahith Reddy, Grewal, Udhayvir Singh, Sheth, Aakash R., Babbili, Akhilesh, Dominic, Paari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187195/
https://www.ncbi.nlm.nih.gov/pubmed/35702660
http://dx.doi.org/10.1097/XCE.0000000000000265
_version_ 1784725118049583104
author Thotamgari, Sahith Reddy
Grewal, Udhayvir Singh
Sheth, Aakash R.
Babbili, Akhilesh
Dominic, Paari
author_facet Thotamgari, Sahith Reddy
Grewal, Udhayvir Singh
Sheth, Aakash R.
Babbili, Akhilesh
Dominic, Paari
author_sort Thotamgari, Sahith Reddy
collection PubMed
description The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database to study the association between AF-related adverse events and the use of GLP-1 RA and DPP-4i. A signal of disproportionate reporting of AF was detected with the DPP-4i group compared with all the other drugs in the FAERS database [ROR, 2.56; 95% confidence interval (CI), 2.10–3.12], whereas there was no disproportionality signal detected with the GLP-1 RA group (ROR, 0.90; 95% CI, 0.78–1.03) although liraglutide showed a significant disproportionality signal (ROR, 2.51; 95% CI, 2.00–3.15). Our analysis supports the existing body of literature demonstrating the cardiac safety of GLP-1 RA but raises concerns about the apparent increase in the risk of AF associated with DPP-4i. Further clinical and translational studies are needed to validate these findings.
format Online
Article
Text
id pubmed-9187195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-91871952022-06-13 Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes? Thotamgari, Sahith Reddy Grewal, Udhayvir Singh Sheth, Aakash R. Babbili, Akhilesh Dominic, Paari Cardiovasc Endocrinol Metab Short Report The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database to study the association between AF-related adverse events and the use of GLP-1 RA and DPP-4i. A signal of disproportionate reporting of AF was detected with the DPP-4i group compared with all the other drugs in the FAERS database [ROR, 2.56; 95% confidence interval (CI), 2.10–3.12], whereas there was no disproportionality signal detected with the GLP-1 RA group (ROR, 0.90; 95% CI, 0.78–1.03) although liraglutide showed a significant disproportionality signal (ROR, 2.51; 95% CI, 2.00–3.15). Our analysis supports the existing body of literature demonstrating the cardiac safety of GLP-1 RA but raises concerns about the apparent increase in the risk of AF associated with DPP-4i. Further clinical and translational studies are needed to validate these findings. Wolters Kluwer Health 2022-06-08 /pmc/articles/PMC9187195/ /pubmed/35702660 http://dx.doi.org/10.1097/XCE.0000000000000265 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Short Report
Thotamgari, Sahith Reddy
Grewal, Udhayvir Singh
Sheth, Aakash R.
Babbili, Akhilesh
Dominic, Paari
Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title_full Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title_fullStr Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title_full_unstemmed Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title_short Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
title_sort can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187195/
https://www.ncbi.nlm.nih.gov/pubmed/35702660
http://dx.doi.org/10.1097/XCE.0000000000000265
work_keys_str_mv AT thotamgarisahithreddy canglucagonlikepeptide1receptoragonistsanddipeptidylpeptidase4inhibitorshelpinmitigatingtheriskofatrialfibrillationinpatientswithdiabetes
AT grewaludhayvirsingh canglucagonlikepeptide1receptoragonistsanddipeptidylpeptidase4inhibitorshelpinmitigatingtheriskofatrialfibrillationinpatientswithdiabetes
AT shethaakashr canglucagonlikepeptide1receptoragonistsanddipeptidylpeptidase4inhibitorshelpinmitigatingtheriskofatrialfibrillationinpatientswithdiabetes
AT babbiliakhilesh canglucagonlikepeptide1receptoragonistsanddipeptidylpeptidase4inhibitorshelpinmitigatingtheriskofatrialfibrillationinpatientswithdiabetes
AT dominicpaari canglucagonlikepeptide1receptoragonistsanddipeptidylpeptidase4inhibitorshelpinmitigatingtheriskofatrialfibrillationinpatientswithdiabetes